Products

BRCA Tumor MASTR™ Plus Dx - Multiplicom

The entire coding region of BRCA1 and BRCA2 in one test

BRCA Tumor MASTR™ Plus Dx is a CE-IVD-labeled molecular diagnostic assay for the identification of mutations in the coding regions of the BRCA1 and BRCA2 genes in cancer patients. 

BRCA1 and BRCA2 can show both germline and somatic mutations. In tumors, mutations in BRCA1and BRCA2 have prognostic value but also predict the response to molecular targeted therapy.

The presence of BRCA1 and BRCA2 mutations pose a vulnerability to cancer cells that is exploited by PARP inhibitors (PARPi). BRCA Tumor MASTR Plus Dx can thus be used as a diagnostic criterion for the treatment with PARPi, which are currently approved for high-grade serous ovarian cancer patients with BRCA1 or BRCA2 mutations in the tumor.

Despite its low prevalence, ovarian cancer is the 5th most lethal tumor in Europe. High-grade serous ovarian cancer is the most common ovarian cancer and associated with BRCA1 or BRCA2mutations in 30 percent of the patients (23 % somatic and 77 % germline mutations). Treatment options are still limited but the advent of targeted therapy gives clinicians and patients new options. Given the effectiveness of targeted therapy, screening for mutations in the BRCA genes in tumor samples becomes increasingly important. The BRCA Tumor MASTR Plus Dx is compatible with DNA isolated from FFPE tumor samples and enables the screening of tumor samples for BRCA mutations.

Show more

http://www.multiplicom.com/product/brca-tumor-mastr-plus-dx#specifications
Petra Kupková

Sales manager

Petra

Kupková

+420 731 426 051

Send Message

Related products

These kits are to be used for the second PCR step to incorporate barcoding and adaptors required for 454 GS Junior or 454 GS FLX instruments (Roche).

show detail

These kits are to be used in combination with the MASTR™ assays.

show detail

The kits are to be used in combination with the MASTR™ assays for the second PCR to incorporate barcoding and adaptors required for the Ion PGM™ System.

show detail

The QC plex assay enables the qualitative and quantitative assessment of human DNA.

show detail

This assay is to be used in combination with the MASTR assays, for applications on

show detail

We supply and support Life-Science Technologies in the territory of Central and Eastern Europe.

Czech Republic

Slovakia

Hungary

Poland

Croatia

Slovenia

Serbia

Romania

Bulgaria

Latvia

Lithuania

Estonia

Russia

Ukraine

Belarus

Turkey